by deyuz | Sep 29, 2025 | White Papers
Prescription drugs have drawn significant policy and public attention in discussions of rising health care costs in the United States. However, their actual contribution to the growth of total health care spending remains uncertain. Drawing on data from the National...
by deyuz | Sep 29, 2025 | White Papers
This policy brief evaluates the potential impact of Most Favored Nation (MFN) pricing on pharmaceutical innovation and patient health. We analyze MFN pricing being imposed in Medicare and Medicaid, requiring U.S. prices for already launched drugs to match the lowest...
by deyuz | Sep 29, 2025 | News Article
By Prof. Em. Tomas J. Philipson Not vice versa. Conventional wisdom holds that prices for prescription drugs paid by our government are substantially higher in the United States than abroad. This has led to various forms of price controls on drugs in the U.S., first...
